Dr. Bradley Welling is a neurotologic surgeon in the Otolaryngology Department's Otology and Neurotology Division, located at Mass. Eye and Ear's main campus on Charles Street. He is the Walter Augustus LeCompte Professor and Chair of Otology and Laryngology at Harvard Medical School and the Chief of Otolaryngology at Mass. Eye and Ear and Mass General. A graduate of the University of Utah, Dr. Welling completed his Otolaryngology residency at the University of Iowa and a fellowship in Otology, Neurotology and Skull Base Surgery at the Ear Foundation at Vanderbilt University. Dr. Welling also earned a Ph.D. in Pathobiology from The Ohio State University.
Dr. Welling's clinical interests involve caring for patients with diseases of the ear and lateral cranial base. More specifically, he focuses on hearing loss, cochlear implants, auditory brainstem implants, as well as facial paralysis and deafness related to Neurofibromatosis type 2 (NF2)-associated tumors. Dr. Welling's research efforts primarily focus on NF2-associated vestibular schwannomas.
Acoustic neuroma: a cost-effective approach. Welling DB, Glasscock ME, Woods CI, Jackson CG. Otolaryngol HNSurg 1990:103(3):364-370.
Mutational spectrum in the neurofibromatosis type 2 gene in sporadic and familial schwannomas. Welling DB, Guida M, Goll F, Pearl DK, Glasscock ME, Pappas DG, Linthicum FH, Rogers D, Prior TW. Hum Genet 1996:98(2): 189-93.
Clinical manifestions of mutations in the neurofibromatosis type 2 gene in vestibular schwannomas. Welling DB. Laryngoscope 1998: 108(2):178-89.
Analysis of the human neurofibromatosis type 2 gene promoter and its expression. Welling DB, Akhmametyeva EM, Daniels RL, Zhu L, Miles-Markley BA, Chang L-S. Otolaryngol HN Surg 2000; 123: 413-418.
cDNA microarray analysis of vestibular schwannomas. Welling DB, Lasak JM, Akhmametyeva EM, Gaheri B, Chang L-S. Otol Neurotol 2002;23(5): 736-748.
Cochlear implantation in the neurofibromatosis type 2 patient: long-term follow-up. Neff BA, Wiet RM, Lasak JM, Ramsden R, Cohen N, Welling DB. Laryngoscope 2007;117:1069-1072.
AR42, A Novel Histone Deacetylase Inhibitor, as a Potential Therapy for Vestibular Schwannomas and Meningiomas. Bush ML, Oblinger J, Brendel, V, Santarelli G, Huang J, Akhmametyeva EM, Burns SS, Wheeler J, Davis J, Chaudhury AR, Kulp S, Chen C-S, Yates C, Chang L-S, Welling DB, Jacob A. Neuro-Oncol 2011; 13:983-989, 2011. PMID: 21778190.
Preclinical Validation of AR42, a Novel Histone Deacetylase Inhibitor, as Treatment for Vestibular Schwannomas. Jacob A, Oblinger J, Bush ML, Brendel V, Santarelli G, Chaudhury AR, Kulp S, La Perle K, Chen C-S, Chang L-S, Welling DB. Laryngoscope 2012;122(1):174-189.
Virtual temporal bone dissection system: OSU virtual temporal bone system: development and testing. Wiet GJ, Stredney D, Kerwin T, Hittle B, Fernandez SA, Abdel-Rasoul M, Welling DB. Laryngoscope 2012; Mar; 122, suppl 1:S1-12. Epub 2012, January 31.
Histone deacetylase inhibitor AR-42 differentially affects cell-cycle transit in meningeal and meningioma cells, potently inhibiting NF2-deficient meningioma growth. Burns SS, Akhmametyeva EM, Oblinger JL, Bush ML, Huang J, Senner V, Chen CS, Jacob A, Welling DB, Chang LS. Cancer Res 2013 Jan 15;73(2):792-803.
A complete list of research publications can be seen at www.pubmed.gov.